New York—March 15, 2011
As a result of its first-ever meeting this past November, APS ACTION determined that distinct variations of APS—which causes frequent abnormal blood clots in arteries and veins —made patient studies into the condition very challenging. Blood clots form because the immune system mistakenly produces antibodies against phospholipid-binding plasma proteins, which puts those affected at risk for stroke and pregnancy complications.
“We concluded there are few controlled clinical trials that have included a heterogeneous group of APS patients who exhibit many different forms of the disease and antiphospholipid antibody test results. Comparison between patients is very difficult when APS looks different from one patient to another,” reported rheumatologist Doruk Erkan, M.D., who is an associate physician-scientist at the Barbara Volcker Center for Women and Rheumatic Disease and clinical co-director of the Mary Kirkland Center for Lupus Care at Hospital for Special Surgery in New York. Dr. Erkan is also the newly-elected Executive Committee Chair of APS ACTION.
Since APS ACTION formed, physicians have been vocal in their determination to advance APS research and treatment and to not be derailed by differences of opinion related to clinical practice.
“I read a post on a Facebook group for APS patients that said, ‘Finally these researchers have started to work together.’ That was sobering,” recalled Dr. Erkan. “While treatment of APS touches on contentious issues, the enthusiasm of APS ACTION participants is palpable. The urgency of the situation calls for a collaborative approach, and we’re working together to improve research, treatment and quality of life for all APS patients.”
The scarcity of comprehensive, well-designed clinical trials involving the condition and its treatment means that evidence-based recommendations to treat APS are hard to come by. In the past, this caused physicians to split into groups that emphasized different treatment regimens. But, it also inspired the creation of APS ACTION.
Emboldened by the newfound consensus of rheumatologists who often differ in their treatment recommendations for individuals with APS, a number of subcommittees have already taken up the challenge to address long-standing issues in APS research.
“The subcommittees have eagerly started to address clinical trial design, an APS patient registry, APS research and outreach to advocacy groups,” said rheumatologist Michael Lockshin, M.D., director of the Barbara Volcker Center for Women and Rheumatic Disease and also co-head of the Mary Kirkland Center for Lupus Research, both at Hospital for Special Surgery. Dr. Lockshin is also one of the executive committee members of APS ACTION.
Dr. Lockshin heads a subcommittee tasked with exploring funding options for maintaining the infrastructure of this international consortium and developing a comprehensive patient registry. “APS ACTION hit the ground running, and we want to keep up this enthusiasm by moving ahead on all APS research-related issues. Members of APS ACTION are dedicated to standardizing clinical care and research and developing evidence-based treatment recommendations, ultimately improving patient outcomes.”
About APS ACTION
Twenty-seven physicians from 19 international centers currently participate in APS ACTION. The number of centers is expected to increase when the infrastructure is finalized. For more information about APS ACTION, physicians and patients may contact Joann Vega (firstname.lastname@example.org or 212-774-2795).
About HSS | Hospital for Special Surgery
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the ninth consecutive year) and No. 3 in rheumatology by U.S.News & World Report (2018-2019). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients and performed more than 32,000 surgical procedures. People from all 50 U.S. states and 80 countries travelled to receive care at HSS. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The culture of innovation is accelerating at HSS as 130 new idea submissions were made to the Global Innovation Institute in 2017 (almost 3x the submissions in 2015). The HSS Education Institute is the world’s leading provider of education on the topic on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.